Quick Answer
Celldex Therapeutics, Inc. reported Operating Income Loss of -$287.37 million for the year ending 2025.
- Celldex Therapeutics, Inc. showed a decrease of -47.3% in Operating Income Loss from 2024 to 2025.
- This data is from Celldex Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$9.29 million | Q3 2010: -$8.88 million | Q1 2011: -$9.66 million | Q2 2011: -$9.88 million | Q3 2011: -$11.48 million | Q1 2012: -$13.29 million | Q2 2012: -$13.49 million | Q3 2012: -$14.75 million | Q1 2013: -$17.40 million | Q2 2013: -$18.66 million | Q3 2013: -$23.27 million | Q1 2014: -$31.49 million | Q2 2014: -$28.55 million | Q3 2014: -$30.34 million | Q1 2015: -$30.98 million | Q2 2015: -$32.75 million | Q3 2015: -$32.37 million | Q1 2016: -$35.70 million | Q2 2016: -$32.37 million | Q3 2016: -$29.99 million | Q1 2017: -$35.11 million | Q2 2017: -$28.93 million | Q3 2017: -$31.96 million | Q1 2018: -$119.68 million | Q2 2018: -$16.87 million | Q3 2018: -$7.76 million | Q1 2019: -$17.94 million | Q2 2019: -$12.26 million | Q3 2019: -$11.84 million | Q1 2020: -$12.87 million | Q2 2020: -$11.37 million | Q3 2020: -$14.34 million | Q1 2021: -$16.64 million | Q2 2021: -$13.44 million | Q3 2021: -$20.82 million | Q1 2022: -$23.26 million | Q2 2022: -$36.40 million | Q3 2022: -$27.70 million | Q1 2023: -$32.47 million | Q2 2023: -$33.21 million | Q3 2023: -$41.24 million | Q1 2024: -$40.61 million | Q2 2024: -$46.32 million | Q3 2024: -$52.13 million | Q1 2025: -$62.74 million | Q2 2025: -$63.86 million | Q3 2025: -$73.62 million.
- Over the full 17 years of available data (2009 to 2025), Celldex Therapeutics, Inc.'s Operating Income Loss has declined by 679.8%.
- Historical annual values: Fiscal year 2025: -$287.37 million | Fiscal year 2024: -$195.08 million | Fiscal year 2023: -$154.54 million | Fiscal year 2022: -$115.23 million | Fiscal year 2021: -$71.24 million | Fiscal year 2020: -$63.35 million | Fiscal year 2019: -$55.03 million | Fiscal year 2018: -$156.44 million | Fiscal year 2017: -$121.53 million | Fiscal year 2016: -$132.92 million | Fiscal year 2015: -$129.54 million | Fiscal year 2014: -$122.43 million | Fiscal year 2013: -$81.44 million | Fiscal year 2012: -$58.08 million | Fiscal year 2011: -$43.40 million | Fiscal year 2010: -$6.46 million | Fiscal year 2009: -$36.85 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: